Corpus Curare Spiritumque
Researcher at the Babraham Institute and the University of Catanzaro “Magna Graecia”, Italy, coordinating an international network of researchers and clinicians from Europe, the United States and Japan, new mechanisms which the immune system recognizes and responds to tumors, such as melanoma. This discovery may therapeutic approaches in the fight against metastatic melanoma, an aggressive form of skin cancer, nearly 2000 deaths in the United Kingdom every year .
This exciting new findings, published in the online edition of the Journal of Clinical Investigation, show how a type of white blood cells – Natural Killer (NK) cells – deals with tumors, characterization for the first time that interactions Molecular, a destruction of melanoma. This has had a melanoma in the understanding of the recognition by the immune system and has the potential of new avenues of research on the prevention of metastases by the use of NK cells’ natural immunity.
Natural killer cells in the blood, lymph nodes and tissues like the liver, lungs and uterus, where they participate in immune defense against infections, cancer, reproductive medicine and success in transplantation medicine. They play an important role in the immune response that targets tumor cells while the healthy cells of economy, the mice showed that NK cells to prevent and fight against tumor growth, whereas in the case of melanoma, the origin of these molecular interactions, such as NK cells and controlling metastatic growth had hitherto always difficult.
The team of scientists led by Francesco Colucci, head of group at the Babraham Institute and Ennio Carbone, University of Catanzaro “Magna Graecia”, Italy, studies of human metastatic melanoma – the aggressive forms of skin cancer on the basis of other pages – mice and spontaneous melanoma.
NK cells sense the signs of infection and detection of abnormal cells, including tumors and their metastases, the receptors on their cell phones. Such a family of natural cytotoxicity receptors (NCRS), such as antennas for detection of molecular cancer research, with the tumors. Two receptors have been identified, the review of the NK-dependent cell killing of melanoma cells. With cell lines from 18 patients with melanoma, the team notes that the production of cell lines of melanoma protein, binding to natural cytotoxicity receptors (NCRS) and a receiver on, that NK-cells DNAX accessory molecule-1 (DNAM-1). These cell lines have been designed to allow destruction of NK cells in vitro and after transplantation in mice. According to the data from human cell lines, mouse and spontaneous melanoma cell lines of melanoma also proteins binding to DNAM-1 and NCRS “affect the ability of the NCRS DNAM-1 and interaction with proteins in melanoma cells through genetic resource or by blocking antibodies, the reduction of NK cells negotiated the killing of human and mouse cell lines of melanoma in vitro and in vivo, “says Dr. Francesco Colucci. “From these results, we have the potential of NK cells in the treatment of melanoma cells and others in the” humanized “mouse, a default method to understand how human cells throughout the body. The results showed that those striking NK cells was able to prevent the death of the mice by the killing of human melanoma cells transplanted.
He added: “We are now creating the next phase of the research program. DNAM-1 and NCRS are parts of the machinery, the NK cell-dependent melanoma cell killing, and show that NK cells could be used to avoid metastatic melanoma. Our objective is to these results to the clinic with new NK cell-based immune therapeutic strategies for treating patients with melanoma, and now, our research to understand fundamental mechanisms, how, when and where the immune system detects early signs of cancer. ”
The research was of Biotechnology and Biological Sciences Research Council (BBSRC), Medical Research Council (UK), Associazione Italiana Ricerca sul cancro (Italy), the Swedish Cancer Society, The Swedish Research Council, the Karolinska Institute and Dr. . Mildred Scheel Foundation for Cancer Research.
Researcher at the Babraham Institute and the University of Catanzaro “Magna Graecia”, Italy, coordinating an international network of researchers and clinicians from Europe, the United States and Japan, new mechanisms which the immune system recognizes and responds to tumors, such as melanoma. This discovery may therapeutic approaches in the fight against metastatic melanoma, an aggressive form of skin cancer, nearly 2000 deaths in the United Kingdom every year .
This exciting new findings, published in the online edition of the Journal of Clinical Investigation, show how a type of white blood cells – Natural Killer (NK) cells – deals with tumors, characterization for the first time that interactions Molecular, a destruction of melanoma. This has had a melanoma in the understanding of the recognition by the immune system and has the potential of new avenues of research on the prevention of metastases by the use of NK cells’ natural immunity.
Natural killer cells in the blood, lymph nodes and tissues like the liver, lungs and uterus, where they participate in immune defense against infections, cancer, reproductive medicine and success in transplantation medicine. They play an important role in the immune response that targets tumor cells while the healthy cells of economy, the mice showed that NK cells to prevent and fight against tumor growth, whereas in the case of melanoma, the origin of these molecular interactions, such as NK cells and controlling metastatic growth had hitherto always difficult.
The team of scientists led by Francesco Colucci, head of group at the Babraham Institute and Ennio Carbone, University of Catanzaro “Magna Graecia”, Italy, studies of human metastatic melanoma – the aggressive forms of skin cancer on the basis of other pages – mice and spontaneous melanoma.
NK cells sense the signs of infection and detection of abnormal cells, including tumors and their metastases, the receptors on their cell phones. Such a family of natural cytotoxicity receptors (NCRS), such as antennas for detection of molecular cancer research, with the tumors. Two receptors have been identified, the review of the NK-dependent cell killing of melanoma cells. With cell lines from 18 patients with melanoma, the team notes that the production of cell lines of melanoma protein, binding to natural cytotoxicity receptors (NCRS) and a receiver on, that NK-cells DNAX accessory molecule-1 (DNAM-1). These cell lines have been designed to allow destruction of NK cells in vitro and after transplantation in mice. According to the data from human cell lines, mouse and spontaneous melanoma cell lines of melanoma also proteins binding to DNAM-1 and NCRS “affect the ability of the NCRS DNAM-1 and interaction with proteins in melanoma cells through genetic resource or by blocking antibodies, the reduction of NK cells negotiated the killing of human and mouse cell lines of melanoma in vitro and in vivo, “says Dr. Francesco Colucci. “From these results, we have the potential of NK cells in the treatment of melanoma cells and others in the” humanized “mouse, a default method to understand how human cells throughout the body. The results showed that those striking NK cells was able to prevent the death of the mice by the killing of human melanoma cells transplanted.
He added: “We are now creating the next phase of the research program. DNAM-1 and NCRS are parts of the machinery, the NK cell-dependent melanoma cell killing, and show that NK cells could be used to avoid metastatic melanoma. Our objective is to these results to the clinic with new NK cell-based immune therapeutic strategies for treating patients with melanoma, and now, our research to understand fundamental mechanisms, how, when and where the immune system detects early signs of cancer. ”
The research was of Biotechnology and Biological Sciences Research Council (BBSRC), Medical Research Council (UK), Associazione Italiana Ricerca sul cancro (Italy), the Swedish Cancer Society, The Swedish Research Council, the Karolinska Institute and Dr. . Mildred Scheel Foundation for Cancer Research.
